Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.

Adacel® is only indicated for patients 10-64 years of age.2

*Tetanus, diphtheria, and acellular pertussis.
U.S. Food and Drug Administration

Adacel is a registered trademark of Sanofi Pasteur group, and its subsidiaries.
Trademarks are owned by or licensed to the GSK group of companies

References:

  1. Prescribing Information for BOOSTRIX.
  2. Prescribing Information for Adacel.
  3. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084-1093.
  4. Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27(5):765-772.
  5. American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.